Stock of the Week – Acadia Pharmaceuticals -($ACAD)

This week’s stock analysis is Acadia Pharmaceuticals – ($ACAD). Acadia Pharmaceuticals is a biopharmaceutical company that primarily focuses on the discovery, development, and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. A central nervous system disorder is a condition that affects the brain and/or spinal cord. Among the most prominent central nervous system disorders are Alzheimer’s Disease, Parkinson’s’ Disease, Multiple Sclerosis, Stroke, Epilepsy, Brain Tumors, Dementia and Schizophrenia. $ACAD’s major product is Nuplazid (pimavanserin), approved in the US for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Recently the FDA approved $ACAD’s Daybe (trofinetide) which is the first and only drug for treating Rett syndrome which is a rare genetic disorder that causes a progressive loss of motor skills and language. Acadia generates revenue primarily from the sale of their approved drugs. This includes both direct sales to consumers and sales to various healthcare and pharmaceutical providers or organizations. The company may also earn revenue from strategic partnerships, licensing agreements, and collaborations with other pharmaceutical or biotech companies. The company was founded in 1993. They have about 500 employees. Some direct competitors include Neurocrine Biosciences, Intra-Cellular Therapies, and Sunovion Pharmaceuticals, among others. The competitive landscape, changes rapidly in the biopharmaceutical industry based upon regulatory challenges, funding and regulatory approvals. In terms of opportunities, Acadia operates in a highly specialized market segment that focuses on unmet medical needs. This could provide significant opportunities as there may be limited competition and a high demand for effective treatments. Their focus on small molecule drugs for central nervous system disorders allows them to potentially address a variety of conditions with high unmet medical needs. On the other hand, Acadia faces several risks common to the pharmaceutical and biotechnology industry. The development and commercialization of new drugs is a costly and time-consuming process with no guaranteed success. Clinical trials can fail, or regulatory bodies such as the FDA may not approve a drug. Even after approval, drugs are subject to ongoing regulatory scrutiny. Additionally, Acadia also faces the risk of competition from other firms developing similar treatments, and the risk of patent expiration, after which generic versions of their drugs can be produced by other companies. Lastly, pricing pressures from healthcare payers and potential changes in healthcare laws and regulations can also impact the company’s profitability. Earnings on $ACAD have grown by 6.4% per year over the past 5 years. Earnings are expected to grow at 72.11% over the coming year. In this stock study we will look at the following metrics and indicators. Wall Street Analysts’ Estimates 52-week high and low boundaries Best Case – Worst Case Analysis Vantagepoint A.I. Forecast (Predictive Blue Line) Neural Network Forecast Daily Range Forecast Intermarket Analysis Our trading suggestion We don’t base our decisions on things like earnings or fundamental cash flow valuations. However, we do look at them to better understand the financial landscape that a company is operating under. Analysts Ratings In our thorough examination of the stock, our first course of action is to understand the perspectives of seasoned professionals who have dedicated their careers to monitoring this asset. We can gain insights into these experts’ views by examining the target price ranges they’ve set for $ACAD. This allows us to gain a firm understanding of their perceived overvalued, fairly valued, and undervalued price points. The 18 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 22.30, with a high estimate of $33.00 and a low estimate of $12.00. The median estimate represents a -7.43% decrease from the last price of $24.09. From this simple analysis we can see that $ACAD is slightly overvalued at the present time but some on Wall Street think that it has the potential to run another $8.84. 52-week High-Low Chart In a conservative context, a 52-week high marks the uppermost price level at which a stock has been traded during the past year. Correspondingly, a 52-week low signifies the lowest trading point reached within the same period. Therefore, when a stock registers a 52-week high, it suggests a positive trend, while hitting a 52-week low implies a negative trend. Why does a 52-week high hold importance? When a stock reaches its 52-week zenith, it prompts investor attention owing to its commendable performance. This holds true when the stock touches a 52-week nadir as well. Such benchmarks serve as essential analytical tools for traders. As traders, it is vital to undertake a detailed evaluation of a stock’s performance, which entails scrutiny of the charts and determining the asset’s standing in relation to its 52-week highs. This is a significant stage in the analysis—it distinguishes robust from the underperforming. Contrary to common perceptions, stocks with superior performance often set new 52-week highs consistently. This suggests market confidence in their potential, with investors demonstrating a positive outlook on their prospects. One of the most straightforward and effective approaches to gauge a stock’s path is to review long-term monthly and weekly charts. By adopting a broader perspective and analyzing a stock’s overall trend, traders can discern patterns and obtain meaningful insights into its trajectory. Numerous successful traders around the globe utilize long-term monthly charts to guide their trend analysis, acknowledging that it offers a holistic picture of a stock’s performance and enables them to make well-informed decisions based on a variety of factors. Over the last 52 weeks $ACAD has traded as high as $25.73 and as low as $12.24. It’s currently trading at its 98th percentile of its 52-week trading range. We also like to divide the annual range ($13.49) by the current price ($25.40) to provide us with a broad estimate of volatility. Currently, the statistical volatility is 53.1%. This metric tells us that if the future behaves like the recent past it would have a very high probability for $ACAD over the next year, to be trading in a range that is 53.1% higher and lower from where it is right now. As savvy traders, we always keep a keen eye on our position within the 52-week trading range. It is a well-known fact that the 52-week high can often present a formidable hurdle for the market, until it is surpassed. In fact, it is not uncommon for stocks to experience a rapid and substantial surge in price shortly after breaching this critical threshold. Stocks that repeatedly break through their 52-week highs multiple times within a given year tend to be in a robust trend and are therefore of great interest to us. The 52-week mark frequently acts as a significant resistance level that can thwart momentum, requiring us to stay laser-focused on the signals generated by our artificial intelligence forecasts. What is potentially very promising about the recent rally in $ACAD is how much potential it has to even revert to its median price of the past decade. The stock was decimated in 2020 and has spent the last 28 months consolidating. Best Case – Worst Case Analysis Moving forward, our intent is to get a real-world perspective of risk and volatility. We can accomplish this by looking at the practical realm of performance and outcomes. We deem it crucial, prior to initiating any trade, to have a comprehensive understanding of how the past year’s rallies compare to the declines. This exercise offers us a glimpse into the actual price movements of $ACAD, aiding us in comprehending its volatility. To realize this goal, we merely link the highest and lowest points to simply understand how the rallies have compared to the declines. First the best-case analysis: Followed by the worst-case analysis: You can quickly observe the level of risk and opportunity by doing this analysis on your own any time you trade. Lastly, we compare the performance of $ACAD to the broader stock market indexes. Clearly, $ACAD massively outperformed the broader stock market indexes across all major important time frames. So, we can conclude that $ACAD deserves to be on your trading radar. Vantagepoint A.I. Forecast (Predictive Blue Line) Using VantagePoint Software and the artificial intelligence, traders are alerted to trend forecasts by monitoring the slope of the predictive blue line. The black line is a simple 10-day moving average of prices which simply tells you what has occurred in the market. The predictive blue line also acts as a value zone where in uptrends traders try to purchase the asset at or below the blue line. When studying the chart below, it’s imperative to consider the interplay between the black line and the predictive blue line. The black line simply provides a historical perspective. It informs you about the past price points and the average price over the previous ten days. Contrastingly, the predictive blue line, backed by Vantagepoint’s proprietary Neural Network and Intermarket Analysis, predicts future values and trends. It harnesses artificial intelligence and employs statistical correlations to identify the most potent price influencers of an asset. Our focus will be on the past six weeks of $ACAD stock, providing an opportunity for you to witness firsthand the remarkable capabilities of artificial intelligence in a live trading scenario. While our approach is conservative, we believe that such technological advancements provide an exciting window into trend analysis and risk management. [Image] Here are Some More Investing Tips and Resources. Enjoy! Sponsored [Own These Stocks Before The Next Bull Run]( It is no secret that the best time to buy stocks is when their prices are low – and our research team has identified a handful of solid businesses with stocks that are currently “on sale” compared to where they were 2 years ago.[Download this FREE Report Revealing These Stocks]( By clicking the link you are subscribing to the Summa Money Newsletter and may receive up to 2 additional free bonus subscriptions. Unsubscribing is easy [Privacy Policy/Disclosures]( [Stock of the Week – Acadia Pharmaceuticals -($ACAD)]( This week’s stock analysis is Acadia Pharmaceuticals – ($ACAD). Acadia Pharmaceuticals is a biopharmaceutical company that primarily focuses on the discovery, development, and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. A central nervous system disorder is a condition that affects the brain and/or spinal cord. Among the most prominent central nervous system disorders are Alzheimer’s Disease, Parkinson’s’ Disease, Multiple Sclerosis, Stroke, Epilepsy, Brain Tumors, Dementia and Schizophrenia. $ACAD’s major product is Nuplazid (pimavanserin), approved in the US for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis. Recently the FDA approved $ACAD’s Daybe (trofinetide) which is the first and only drug for treating Rett syndrome which is a rare genetic disorder that causes a progressive loss of motor skills and language. Acadia generates revenue primarily from the sale of their approved drugs. This includes both direct sales to consumers and sales to various healthcare and pharmaceutical providers or organizations. The company may also earn revenue from strategic partnerships, licensing agreements, and collaborations with other pharmaceutical or biotech companies. The company was founded in 1993. They have about 500 employees. Some direct competitors include Neurocrine Biosciences, Intra-Cellular Therapies, and Sunovion Pharmaceuticals, among others. The competitive landscape, changes rapidly in the biopharmaceutical industry based upon regulatory challenges, funding and regulatory approvals. In terms of opportunities, Acadia operates in a highly specialized market segment that focuses on unmet medical needs. This could provide significant opportunities as there may be limited competition and a high demand for effective treatments. Their focus on small molecule drugs for central nervous system disorders allows them to potentially address a variety of conditions with high unmet medical needs. On the other hand, Acadia faces several risks common to the pharmaceutical and biotechnology industry. The development and commercialization of new drugs is a costly and time-consuming process with no guaranteed success. Clinical trials can fail, or regulatory bodies such as the FDA may not approve a drug. Even after approval, drugs are subject to ongoing regulatory scrutiny. Additionally, Acadia also faces the risk of competition from other firms developing similar treatments, and the risk of patent expiration, after which generic versions of their drugs can be produced by other companies. Lastly, pricing pressures from healthcare payers and potential changes in healthcare laws and regulations can also impact the company’s profitability. Earnings on $ACAD have grown by 6.4% per year over the past 5 years. Earnings are expected to grow at 72.11% over the coming year. In this stock study we will look at the following metrics and indicators. Wall Street Analysts’ Estimates 52-week high and low boundaries Best Case – Worst Case Analysis Vantagepoint A.I. Forecast (Predictive Blue Line) Neural Network Forecast Daily Range Forecast Intermarket Analysis Our trading suggestion We don’t base our decisions on things like earnings or fundamental cash flow valuations. However, we do look at them to better understand the financial landscape that a company is operating under. Analysts Ratings In our thorough examination of the stock, our first course of action is to understand the perspectives of seasoned professionals who have dedicated their careers to monitoring this asset. We can gain insights into these experts’ views by examining the target price ranges they’ve set for $ACAD. This allows us to gain a firm understanding of their perceived overvalued, fairly valued, and undervalued price points. The 18 analysts offering 12-month price forecasts for ACADIA Pharmaceuticals Inc have a median target of 22.30, with a high estimate of $33.00 and a low estimate of $12.00. The median estimate represents a -7.43% decrease from the last price of $24.09. From this simple analysis we can see that $ACAD is slightly overvalued at the present time but some on Wall Street think that it has the potential to run another $8.84. 52-week High-Low Chart In a conservative context, a 52-week high marks the uppermost price level at which a stock has been traded during the past year. Correspondingly, a 52-week low signifies the lowest trading point reached within the same period. Therefore, when a stock registers a 52-week high, it suggests a positive trend, while hitting a 52-week low implies a negative trend. Why does a 52-week high hold importance? When a stock reaches its 52-week zenith, it prompts investor attention owing to its commendable performance. This holds true when the stock touches a 52-week nadir as well. Such benchmarks serve as essential analytical tools for traders. As traders, it is vital to undertake a detailed evaluation of a stock’s performance, which entails scrutiny of the charts and determining the asset’s standing in relation to its 52-week highs. This is a significant stage in the analysis—it distinguishes robust from the underperforming. Contrary to common perceptions, stocks with superior performance often set new 52-week highs consistently. This suggests market confidence in their potential, with investors demonstrating a positive outlook on their prospects. One of the most straightforward and effective approaches to gauge a stock’s path is to review long-term monthly and weekly charts. By adopting a broader perspective and analyzing a stock’s overall trend, traders can discern patterns and obtain meaningful insights into its trajectory. Numerous successful traders around the globe utilize long-term monthly charts to guide their trend analysis, acknowledging that it offers a holistic picture of a stock’s performance and enables them to make well-informed decisions based on a variety of factors. Over the last 52 weeks $ACAD has traded as high as $25.73 and as low as $12.24. It’s currently trading at its 98th percentile of its 52-week trading range. We also like to divide the annual range ($13.49) by the current price ($25.40) to provide us with a broad estimate of volatility. Currently, the statistical volatility is 53.1%. This metric tells us that if the future behaves like the recent past it would have a very high probability for $ACAD over the next year, to be trading in a range that is 53.1% higher and lower from where it is right now. As savvy traders, we always keep a keen eye on our position within the 52-week trading range. It is a well-known fact that the 52-week high can often present a formidable hurdle for the market, until it is surpassed. In fact, it is not uncommon for stocks to experience a rapid and substantial surge in price shortly after breaching this critical threshold. Stocks that repeatedly break through their 52-week highs multiple times within a given year tend to be in a robust trend and are therefore of great interest to us. The 52-week mark frequently acts as a significant resistance level that can thwart momentum, requiring us to stay laser-focused on the signals generated by our artificial intelligence forecasts. What is potentially very promising about the recent rally in $ACAD is how much potential it has to even revert to its median price of the past decade. The stock was decimated in 2020 and has spent the last 28 months consolidating. Best Case – Worst Case Analysis Moving forward, our intent is to get a real-world perspective of risk and volatility. We can accomplish this by looking at the practical realm of performance and outcomes. We deem it crucial, prior to initiating any trade, to have a comprehensive understanding of how the past year’s rallies compare to the declines. This exercise offers us a glimpse into the actual price movements of $ACAD, aiding us in comprehending its volatility. To realize this goal, we merely link the highest and lowest points to simply understand how the rallies have compared to the declines. First the best-case analysis: Followed by the worst-case analysis: You can quickly observe the level of risk and opportunity by doing this analysis on your own any time you trade. Lastly, we compare the performance of $ACAD to the broader stock market indexes. Clearly, $ACAD massively outperformed the broader stock market indexes across all major important time frames. So, we can conclude that $ACAD deserves to be on your trading radar. Vantagepoint A.I. Forecast (Predictive Blue Line) Using VantagePoint Software and the artificial intelligence, traders are alerted to trend forecasts by monitoring the slope of the predictive blue line. The black line is a simple 10-day moving average of prices which simply tells you what has occurred in the market. The predictive blue line also acts as a value zone where in uptrends traders try to purchase the asset at or below the blue line. When studying the chart below, it’s imperative to consider the interplay between the black line and the predictive blue line. The black line simply provides a historical perspective. It informs you about the past price points and the average price over the previous ten days. Contrastingly, the predictive blue line, backed by Vantagepoint’s proprietary Neural Network and Intermarket Analysis, predicts future values and trends. It harnesses artificial intelligence and employs statistical correlations to identify the most potent price influencers of an asset. Our focus will be on the past six weeks of $ACAD stock, providing an opportunity for you to witness firsthand the remarkable capabilities of artificial intelligence in a live trading scenario. While our approach is conservative, we believe that such technological advancements provide an exciting window into trend analysis and risk management. [Continue Reading...]( [Stock of the Week – Acadia Pharmaceuticals -($ACAD)]( And, in case you missed it: - [Uniswap is Live on Coinrule]( - [Crypto Winter and the Stages of Grief]( - [Understanding the Impact of the Best US Dollar Rate]( - [Commodity Trading and its Role in Energy Transition]( - [“Goldman Sachs’ Share Price Sparks Investor Buzz”]( - FREE OR LOW COST INVESTING RESOURCES - [i]( [i]( [i]( [i]( Sponsored [Fed’s Shocking New Plan to Control Your Money]( The Federal Reserve has a disturbing plan that is getting ready to roll out as soon as July. This is a lot more than printing trillions of dollars or manipulating interest rates. It’s about every checking account, every purchase and every money transfer in America — including yours and mine.  [Click here to discover how to protect your money]( [Privacy Policy/Disclosures]( - CLICK THE IMAGE BELOW FOR MORE INFORMATION - [i]( Good Investing! T. D. Thompson Founder & CEO [ProfitableInvestingTips.com]() ProfitableInvestingTips.com is an informational website for men and women who want to discover investing and trading products and strategies to educate themselves about the risks and benefits of investing and investing-related products. DISCLAIMER: Use of this Publisher's email, website and content, is subject to the Privacy Policy and Terms of Use published on Publisher's Website. Content marked as "sponsored" may be third party advertisements and are not endorsed or warranted by our staff or company. The content in our emails is for informational or entertainment use, and is not a substitute for professional advice. Always check with a qualified professional regarding investing and trading guidance. Be sure to do your own careful research before taking action based on anything you find in this content. If you no longer wish to receive our emails, click the link below: [Unsubscribe]( Net Wealth Consultants 6614 La Mora Drive Houston, Texas 77083 United States (888) 983-9123